Mobile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002831-14

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the pharmacologically active dose (PAD) and maximum tolerated dose (MTD) of INCB054828, alone as a monotherapy and in combination with other therapies. To assess the pharmacodynamics (PD) of INCB054828.

Critère d'inclusion

  • advanced malignancies

Liens